MARKET

TBPH

TBPH

Theravance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.62
+0.20
+0.93%
After Hours: 21.62 0 0.00% 16:00 07/10 EDT
OPEN
21.52
PREV CLOSE
21.42
HIGH
22.20
LOW
21.26
VOLUME
395.72K
TURNOVER
--
52 WEEK HIGH
31.54
52 WEEK LOW
15.72
MARKET CAP
1.36B
P/E (TTM)
-4.9935
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TBPH stock price target is 33.22 with a high estimate of 42.00 and a low estimate of 20.00.

EPS

TBPH News

More
JP Morgan Initiates Coverage On Theravance Biopharma with Overweight Rating, Announces Price Target of $29
JP Morgan initiates coverage on Theravance Biopharma (NASDAQ:TBPH) with a Overweight rating and announces Price Target of $29.
Benzinga · 3d ago
Theravance Biopharma initiated at overweight with $29 price target at JPMorgan
marketwatch.com · 3d ago
How R&D Expenses Can Help You Pick Outperforming Stocks
Seeking Alpha - Article · 07/02 16:13
Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced the appointment of
PR Newswire · 07/02 10:00
Hedge Funds Have Never Been More Bullish On Theravance Biopharma Inc (TBPH)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These fi
Insider Monkey · 06/29 19:50
Theravance Doses First Patient in Phase II Coronavirus Study
Zacks · 06/26 17:04
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
Benzinga · 06/25 13:26
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24)
Benzinga · 06/25 12:26

Industry

Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About TBPH

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
More

Webull offers kinds of Theravance Biopharma Inc stock information, including NASDAQ:TBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TBPH stock methods without spending real money on the virtual paper trading platform.